Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350

Mok, Hoyin; Cheng, Xing; Xu, Qi; Zengel, James R; Parhy, Bandita; Zhao, Jackie; Wang, C. Kathy; Jin, Hong

Rhesus macaque study. Adult rhesus macaques aged 3-9 year-old were used for the immunogenicity study at Valley Biosystems (West Sacramento, CA). All experimental procedures were approved by the Institutional Animal Use and Care Committee at MedImmune and Valley Biosystems. Measles vaccine immunization history of the rhesus macaques was confirmed by neutralization assay prior to the study. A total of 16 rhesus macaques (8 measles virus seropositive, 8 naïve) were used in the study. Half of the animals (4 measles virus sero-positive, 4 naïve) received two doses of gp350 intramuscularly using 10 5 PFU/inoculation and the other half received two doses of sF3 at the same dose intramuscularly. The inoculations were performed at 4 week intervals. Blood was drawn from each animal every 14 days to assess immune responses. Animals were anesthetized with ketamine intramuscularly at each procedure. Clinical symptoms were monitored by veterinarians for the duration of the study.